Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Ductal carcinoma in situ (DCIS) is the most common type of non-invasive breast cancer. DCIS is not life threatening but can increase the risk of invasive ductal carcinoma (IDC) development. However, the role of P53 expression in the progression to invasiveness in DCIS is unclear. In this retrospective study, the differences in biological markers, including protein 53 (P53) expressions, between DCIS and IDC ≤5 mm in diameter (T1a) were evaluated. Among 2,497 primary breast cancer patients, who underwent initial surgery between 2001 and 2010, 267 (10.4%) patients were diagnosed with DCIS and 86 (3.4%) patients were diagnosed with T1a.
citation: Kikuchi S, Osako T, Nishiyama Y, Nakano M, Tashima R, et al. (2014) P53 Overexpression in Ductal Carcinoma in situ of the Breast. J Cytol Histol 5:269.